These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 29040800)

  • 1. Ocriplasmin for symptomatic vitreomacular adhesion.
    Neffendorf JE; Kirthi V; Pringle E; Jackson TL
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Smith JM; Steel DH
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
    Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
    Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pars plana vitrectomy versus scleral buckling for repairing simple rhegmatogenous retinal detachments.
    Znaor L; Medic A; Binder S; Vucinovic A; Marin Lovric J; Puljak L
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009562. PubMed ID: 30848830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
    Evans JR; Lawrenson JG
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD000254. PubMed ID: 28756618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
    Dervenis P; Dervenis N; Smith JM; Steel DH
    Cochrane Database Syst Rev; 2023 May; 5(5):CD008214. PubMed ID: 37260074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Martinez-Zapata MJ; Martí-Carvajal AJ; Solà I; Pijoán JI; Buil-Calvo JA; Cordero JA; Evans JR
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008721. PubMed ID: 25418485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitrectomy with internal limiting membrane (ILM) peeling versus vitrectomy with no peeling for idiopathic full-thickness macular hole (FTMH).
    Spiteri Cornish K; Lois N; Scott N; Burr J; Cook J; Boachie C; Tadayoni R; la Cour M; Christensen U; Kwok A
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009306. PubMed ID: 23740611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters.
    Kokavec J; Wu Z; Sherwin JC; Ang AJ; Ang GS
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011676. PubMed ID: 28570745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
    N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
    Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
    Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Face-down positioning or posturing after pars plana vitrectomy for macula-involving rhegmatogenous retinal detachments.
    Fung TH; Yim TW; Lois N; Wright DM; Liu SH; Williamson T
    Cochrane Database Syst Rev; 2024 Mar; 3(3):CD015514. PubMed ID: 38488250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.
    Schwartz SG; Flynn HW; Wang X; Kuriyan AE; Abariga SA; Lee WH
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006126. PubMed ID: 32408387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
    Varma R; Haller JA; Kaiser PK
    JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.